Literature DB >> 2521733

Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets.

T M Palabrica1, B C Furie, M A Konstam, M J Aronovitz, R Connolly, B A Brockway, K L Ramberg, B Furie.   

Abstract

The activated platelet is a potential target for the localization of thrombi in vivo since, after stimulation and secretion of granule contents, activated platelets are concentrated at sites of blood clot formation. In this study, we used antibodies specific for a membrane protein of activated platelets to detect experimental thrombi in an animal model. PADGEM (platelet activation-dependent granule-external membrane protein), a platelet alpha-granule membrane protein, is translocated to the plasma membrane during platelet activation and granule secretion. Since PADGEM is internal in unstimulated platelets, polyclonal anti-PADGEM and monoclonal KC4 antibodies do not bind to circulating resting platelets but do interact with activated platelets. Dacron graft material incubated with radiolabeled KC4 or anti-PADGEM antibodies in the presence of thrombin-activated platelet-rich plasma bound most of the antibody. Imaging experiments with 123I-labeled anti-PADGEM in baboons with an external arterial-venous Dacron shunt revealed rapid uptake in the thrombus induced by the Dacron graft; control experiments with 123I-labeled nonimmune IgG exhibited minimal uptake. Deep venous thrombi, formed by using percutaneous balloon catheters to stop blood flow in the femoral vein of baboons, were visualized with 123I-labeled anti-PADGEM. Thrombi were discernible against blood pool background activity without subtraction techniques within 1 hr. No target enhancement was seen with 123I-labeled nonimmune IgG. 123I-labeled anti-PADGEM cleared the blood pool with an initial half-disappearance time of 6 min and did not interfere with hemostasis. These results indicate that radioimmunoscintigraphy with anti-PADGEM antibodies can visualize thrombi in baboon models and is a promising technique for clinical thrombus detection in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521733      PMCID: PMC286616          DOI: 10.1073/pnas.86.3.1036

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  PADGEM protein.

Authors:  C L Berman; E L Yeo; B C Furie; B Furie
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

2.  Evaluation of monoclonal antifibrin antibodies by their binding to human blood clots.

Authors:  C S Liau; E Haber; G R Matsueda
Journal:  Thromb Haemost       Date:  1987-02-03       Impact factor: 5.249

3.  A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets.

Authors:  S Hsu-Lin; C L Berman; B C Furie; D August; B Furie
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

4.  Antibody-directed urokinase: a specific fibrinolytic agent.

Authors:  C Bode; G R Matsueda; K Y Hui; E Haber
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

Review 5.  Molecular defects in interactions of platelets with the vessel wall.

Authors:  J N George; A T Nurden; D R Phillips
Journal:  N Engl J Med       Date:  1984-10-25       Impact factor: 91.245

6.  Radioimmunoimaging of experimental thrombi in dogs using technetium-99m-labeled monoclonal antibody fragments reactive with human platelets.

Authors:  P Som; Z H Oster; P O Zamora; K Yamamoto; D F Sacker; A B Brill; K D Newell; B A Rhodes
Journal:  J Nucl Med       Date:  1986-08       Impact factor: 10.057

7.  Indium-111 platelet scintigraphy for the diagnosis of acute venous thrombosis.

Authors:  M D Ezekowitz; C F Pope; H D Sostman; E O Smith; M Glickman; S Rapoport; K W Sniderman; G Friedlaender; R R Pelker; F B Taylor
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

8.  Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibody.

Authors:  Z H Oster; S C Srivastava; P Som; G E Meinken; L E Scudder; K Yamamoto; H L Atkins; A B Brill; B S Coller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

9.  Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor.

Authors:  B S Coller; L E Scudder
Journal:  Blood       Date:  1985-12       Impact factor: 22.113

10.  A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation.

Authors:  P E Stenberg; R P McEver; M A Shuman; Y V Jacques; D F Bainton
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

View more
  7 in total

Review 1.  Immunoscintigraphy of thrombosis.

Authors:  M N Wasser; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1990

2.  The association of P-selectin glycoprotein ligand-1 VNTR polymorphisms with coronary stent restenosis.

Authors:  Beste Ozben; Reyhan Diz-Kucukkaya; Ahmet K Bilge; Veysel S Hancer; Aytac Oncul
Journal:  J Thromb Thrombolysis       Date:  2007-06       Impact factor: 2.300

Review 3.  Will complex carbohydrate ligands of vascular selectins be the next generation of non-steroidal anti-inflammatory drugs?

Authors:  J L Winkelhake
Journal:  Glycoconj J       Date:  1991-10       Impact factor: 2.916

4.  Synthesis and Biological Evaluation of Cyclic [99mTc]-HYNIC-CGPRPPC as a Fibrin-Binding Peptide for Molecular Imaging of Thrombosis and Its Comparison with [99mTc]-HYNIC-GPRPP.

Authors:  Sedigheh Rezaeianpour; Atefeh Hajiagha Bozorgi; Abolghasem Moghimi; Ameneh Almasi; Saeed Balalaie; Sorour Ramezanpour; Sanaz Nasoohi; Seyed Mohammad Mazidi; Parham Geramifar; Ahmad Bitarafan-Rajabi; Soraya Shahhosseini
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

Review 5.  Rationale for the rational development of new cardiac imaging agents.

Authors:  D D Miller
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

6.  S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo.

Authors:  E Salas; E J Langford; M T Marrinan; J F Martin; S Moncada; A J de Belder
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

7.  A potential target gene CD63 for different degrees of intervertebral disc degeneration.

Authors:  Sheng Gao; Shu Jia; Xutao Fan; Chengcan Gao; Qingwei Li; Yuxue Wu; Chunyang Meng
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.